Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms

Epigenomics

Volumn 8, Issue 1, 2016, Pages 55-66

  Wong Doo, Nicole ^a,b   Makalic, Enes ^c   Joo, Jihoon E ^c   Vajdic, Claire M ^d   Schmidt, Daniel F ^c   Wong, Ee Ming ^c   Jung, Chol Hee ^c   Severi, Gianluca ^e   Park, Daniel J ^c   Chung, Jessica ^c   Baglietto, Laura ^a,c   Prince, Henry Miles ^c,f   Seymour, John F ^c,f   Tam, Constantine ^f   Hopper, John L ^c   English, Dallas R ^a,c   Milne, Roger L ^a,c   Harrison, Simon J ^f   Southey, Melissa C ^c   Giles, Graham G ^a,c  

^a CANCER EPIDEMIOLOGY CENTRE   (Australia)

^b Concord General and Repatriation Hospital ^*  (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e Human Genetics Foundation   (Italy)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

B cell neoplasms; DNA methylation; lymphoma; peripheral blood methylation

Indexed keywords

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD ANALYSIS; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CPG ISLAND; DNA EXTRACTION; DNA METHYLATION; GENOME; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; TUMOR SUPPRESSOR GENE; B LYMPHOCYTE; BLOOD; FEMALE; GENETIC PREDISPOSITION; GENETICS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY;

CADHERIN; CDH1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; PCDH10 PROTEIN, HUMAN; TRANSCRIPTION FACTOR HOXA9;

ADULT; AGED; B-LYMPHOCYTES; CADHERINS; CASE-CONTROL STUDIES; CPG ISLANDS; DNA METHYLATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMEODOMAIN PROTEINS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES;

EID: 84954477184     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.15.97     Document Type: Article

References (45)

1. Swerdlow S, Swerdlow E, Harris N et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon, France (2008).
2. SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. http://seer.Cancer.Gov/csr/1975-2012/
3. Yuille MR, Matutes E, Marossy A, Hilditch B, Catovsky D, Houlston RS. Familial chronic lymphocytic leukaemia: a survey and review of published studies. Br. J. Haematol. 109(4), 794-799 (2000).
4. Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish family-cancer database. Blood 104(6), 1850-1854 (2004).
5. Landgren O, Kristinsson SY, Goldin LR et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in sweden. Blood 114(4), 791-795 (2009).
6. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349(21), 2042-2054 (2003).
7. Martín-Subero JI, Kreuz M, Bibikova M et al. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 113(11), 2488-2497 (2009).
8. Walker BA, Wardell CP, Chiecchio L et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 117(2), 553-562 (2011).
9. Kanduri M, Cahill N, Goransson H et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood 115(2), 296-305 (2010).
10. Salhia B, Baker A, Ahmann G, Auclair D, Fonseca R, Carpten J. DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. Cancer Res. 70(17), 6934-6944 (2010).
11. Martin-Subero JI, Ammerpohl O, Bibikova M et al. A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS ONE 4(9), e6986 (2009).
12. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 395(6697), 89-93 (1998).
13. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev. Cell 19(5), 698-711 (2010).
14. Park G, Kang SH, Lee JH et al. Concurrent p16 methylation pattern as an adverse prognostic factor in multiple myeloma: a methylation-specific polymerase chain reaction study using two different primer sets. Ann. Hematol. 90(1), 73-79 (2011).
15. Braggio E, Maiolino A, Gouveia ME et al. Methylation status of nine tumor suppressor genes in multiple myeloma. Int. J. Hematol. 91(1), 87-96 (2010).
16. Kocemba KA, Groen RW, Van Andel H et al. Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma. PLoS ONE 7(2), e30359 (2012).
17. Dawson S-J, Tsui DWY, Murtaza M et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368(13), 1199-1209 (2013).
18. Woo HD, Kim J. Global DNA hypomethylation in peripheral blood leukocytes as a biomarker for cancer risk: a meta-analysis. PLoS ONE 7(4), e34615 (2012).
19. Giachelia M, Bozzoli V, D'Alo F et al. Quantification of DAPK1 promoter methylation in bone marrow and peripheral blood as a follicular lymphoma biomarker. J. Mol. Diagn. 16(4), 467-476 (2014).
20. Joo JE, Wong EM, Baglietto L et al. The use of DNA from archival dried blood spots with the Infinium Humanmethylation450 array. BMC Biotechnol. 13, 23 (2013).
21. Giles GG, English DR. The Melbourne Collaborative Cohort Study. IARC Sci. Publ. 156, 69-70 (2002).
22. R Core Team, R Foundation for Statistical Computing, 2015. www.r-project.org
23. Aryee MJ, Jaffe AE, Corrada-Bravo H et al. Minfi: a flexible and comprehensive bioconductor package for the analysis of infinium DNA methylation microarrays. Bioinformatics 30(10), 1363-1369 (2014).
24. Maksimovic J, Gordon L, Oshlack A. Swan: subsetquantile within array normalization for illumina infinium humanmethylation450 beadchips. Genome Biol. 13(6), R44 (2012).
25. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical bayes methods. Biostatistics 8(1), 118-127 (2007).
26. Marabita F, Almgren M, Lindholm ME et al. An evaluation of analysis pipelines for DNA methylation profiling using the Illumina Humanmethylation450 beadchip platform. Epigenetics 8(3), 333-346 (2013).
27. Naeem H, Wong NC, Chatterton Z et al. Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the humanmethylation450 array. BMC Genomics 15, 51 (2014).
28. Du P, Zhang X, Huang CC et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 11, 587 (2010).
29. Weber M, Hellmann I, Stadler MB et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat. Genet. 39(4), 457-466 (2007).
30. Martin-Subero JI, Kreuz M, Bibikova M et al. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 113(11), 2488-2497 (2009).
31. Price ME, Cotton AM, Lam LL et al. Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium Humanmethylation450 beadchip array. Epigenetics Chromatin 6(1), 4 (2013).
32. Houseman EA, Accomando WP, Koestler DC et al. DNA methylation arrays as surro-gate measures of cell mixture distribution. BMC Bioinformatics 13(1), 86 (2012).
33. Choi JH, Li Y, Guo J et al. Genome-wide DNA methylation maps in follicular lymphoma cells determined by methylation-enriched bisulfite sequencing. PLoS ONE 5(9), e13020 (2010).
34. Narayan G, Xie D, Freddy AJ et al. PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis. Genes Chromosomes Cancer 52(11), 1030-1041 (2013).
35. Halldorsdottir AM, Kanduri M, Marincevic M et al. Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia. Am. J. Hematol. 87(4), 361-367 (2012).
36. Handa H, Tahara K, Shimizu H et al. Chromosome 16q located genes CDH1, CDH13 and ADAMTS18 are correlated and frequently methylated but not associated with dnmts levels in human lymphoma. Blood 122, 4289-4289 (2013).
37. Dudbridge F, Gusnanto A. Estimation of significance thresholds for genomewide association scans. Genet. Epidemiol. 32(3), 227-234 (2008).
38. O'Riain C, O'Shea DM, Yang Y et al. Array-based DNA methylation profiling in follicular lymphoma. Leukemia 23(10), 1858-1866 (2009).
39. Cahill N, Bergh AC, Kanduri M et al. 450k-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. Leukemia 27(1), 150-158 (2013).
40. Irizarry RA, Ladd-Acosta C, Wen B et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41(2), 178-186 (2009).
41. Reinius LE, Acevedo N, Joerink M et al. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. PLoS ONE 7(7), e41361 (2012).
42. Koestler DC, Christensen B, Karagas MR et al. Bloodbased profiles of DNA methylation predict the underlying distribution of cell types: a validation analysis. Epigenetics 8(8), 816-826 (2013).
43. Jaffe AE, Irizarry RA. Accounting for cellular heterogeneity is critical in epigenome-wide association studies. Genome Biol. 15(2), R31 (2014).
44. Hughes T, Ture-Ozdemir F, Alibaz-Oner F, Coit P, Direskeneli H, Sawalha AH. Epigenome-wide scan identifies a treatment-responsive pattern of altered DNA methylation among cytoskeletal remodeling genes in monocytes and CD4+ T cells in behcet's disease. Arthritis Rheumatol. 66(6), 1648-1658 (2014).
45. Altorok N, Coit P, Hughes T et al. Genome-wide DNA methylation patterns in naive CD4+ T cells from patients with primary sjögren's syndrome. Arthritis Rheumatol. 66(3), 731-739 (2014).